An annual review of the remarkable advances in lung cancer clinical research in 2019

被引：31

作者：

Cheng, Bo ^{[1
,2
]}

Xiong, Shan ^{[1
,2
]}

Li, Caichen ^{[1
,2
]}

Liang, Hengrui ^{[1
,2
]}

Zhao, Yi ^{[1
,2
]}

Li, Jianfu ^{[1
,2
]}

Shi, Jiang ^{[1
,2
]}

Ou, Limin ^{[1
,2
]}

Chen, Zisheng ^{[1
,2
,3
]}

Liang, Peng ^{[1
,2
]}

Liang, Wenhua ^{[1
,2
]}

He, Jianxing ^{[1
,2
]}

机构：

[1] Guangzhou Med Univ, State Key Lab Resp Dis, Affiliated Hosp 1, Dept Thorac Surg & Oncol, Guangzhou 510120, Peoples R China

[2] Natl Clin Res Ctr Resp Dis, Guangzhou 510120, Peoples R China

[3] Guangzhou Med Univ, Qingyuan Peoples Hosp, Affiliated Hosp 6, Dept Resp Med, Qingyuan 511500, Peoples R China

来源：

JOURNAL OF THORACIC DISEASE | 2020年 / 12卷 / 03期

关键词：

Lung cancer; clinical trial; chemotherapy; immunotherapy; targeted therapy; PLATINUM-BASED CHEMOTHERAPY; INTEGRATED ANALYSIS; OPEN-LABEL; EGFR-TKI; SURVIVAL; ENTRECTINIB; ASSOCIATION; SINTILIMAB; EFFICACY; OUTCOMES;

D O I：

10.21037/jtd.2020.03.11

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

In recent years, lung cancer has become the most common cancer and the leading cause of deaths attributed to cancer. in China, lung cancer is the third leading cause of death after strokes and ischemic heart disease. This review aimed to provide an up-to-date summary of studies in regard to lung cancer in 2019 and to present the remarkable progress seen in lung cancer clinical research. A systematic search of PubMed and Web of Science for research published in 2019 was conducted using the search terms "lung cancer", "early stage", "advanced", "diagnosis", "treatment", or any combination of these terms. We selected 56 studies that we considered to be significant and have presented their major findings. In summary, survival among lung cancer patients was significantly improved compared with historical controls, turning lung cancer from an incurable disease into a chronic disease. In addition, treating lung cancer has become increasingly comprehensive, diversified, and individualized. Exploring the accurate biomarkers in immunotherapy and the mechanism of drug resistance in targeted therapy constitutes the greatest challenge at this stage.

引用

页码：1056 / 1069

页数：14

共 56 条

[1]